Journal of Microbiology

, Volume 51, Issue 4, pp 448–452 | Cite as

Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia

  • Alba A. TrespalaciosEmail author
  • William Otero
  • Jorge E. Caminos
  • Marcela M. Mercado
  • Jenny Ávila
  • Liliana E. Rosero
  • Azucena Arévalo
  • Raúl A. Poutou-Piñales
  • David Y. Graham
Microbial Genetics, Genomics and Molecular Biology


Resistance of Helicobacter pylori to clarithromycin is the most common cause of treatment failure in patients with H. pylori infections. This study describes the MICs and the presence of 23S rRNA mutations of H. pylori isolates from Bogotá, D.C., Colombia. H. pylori were isolated from gastric biopsies from patients with functional dyspepsia. Clarithromycin susceptibility was investigated by agar dilution and strains were considered resistant if the MIC was ≥1 μg/ml. DNA sequences of the 23S rRNA gene of strains resistant and sensitive to clarithromycin were determined to identify specific point mutations. Clarithromycin resistance was present in 13.6% of patients by agar dilution. The A2143G, A2142G and A2142C mutations were found in 90.5, 7.1, and 2.4% of H. pylori strains with resistance genotype.The resistant phenotype was associated with 23S rRNA resistance genotype in 85.7% of isolates. The point mutations in 23S rRNA were well correlated with MICs values for clarithromycin.


Helicobacter pylori clarithromycin resistance 23S rRNA mutations 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agudo, S., Perez-Perez, G., Alarcón, T., and López-Brea, M. 2010. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J. Clin. Microbiol. 48, 3703–3707.PubMedCrossRefGoogle Scholar
  2. Alarcón, T., Domingo, D., Prieto, N., and López-Brea, M. 2000. Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC and type of mutation in the 23S rRNA. J. Antimicrob. Chemother. 46, 613–616.PubMedCrossRefGoogle Scholar
  3. Alarcón, T., Domingo, D., Prieto, N., de la Obra, P., and López-Brea, M. 2002. Actividad in vitro de claritromicina y metronidazol frente a Helicobacter pylori en diferentes atmósferas de incubación. Rev. Españala de Quimioterapia. 15, 341–345.Google Scholar
  4. álvarez, A., Moncayo, J.I., Santacruz, J.J., Corredor, L.F., Reinosa, E., Martínez, J.W., and Beltrán, L. 2009a. Resistencia a metronidazol y claritromicina en aislamientos de Helicobacter pylori de pacientes dispépticos en Colombia. Rev. Méd. Chile 137, 1309–1314.PubMedGoogle Scholar
  5. álvarez, A., Moncayo, J.I., Santacruz, J.J., Santacoloma, M., Corredor, L.F., and Reinosa, E. 2009b. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob. Agent Chemother. 53, 4022–4024.CrossRefGoogle Scholar
  6. Ansorg, R., Von Recklinghausen, G., Pomarius, R., and Schmid, E.N. 1991. Evaluation of techniques for isolation, subcultivation, and preservation of Helicobacter pylori. J. Clin. Microbiol. 29, 51–53.PubMedGoogle Scholar
  7. Arévalo-Galvis, A., Trespalacios-Rangel, A.A., Otero, W., Mercado-Reyes, M., and Poutou-Piñales, R.A. 2012. PPrevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol. J. Microbiol. 61, 33–40.PubMedGoogle Scholar
  8. Barile, K.A., Silva, A.L., Xavier, J.N., Assumpção, M.B., and Corvelo, T.C. 2010. Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon. Mem. Inst. Oswaldo Cruz. 105, 314–317.PubMedGoogle Scholar
  9. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20.Google Scholar
  10. Correa, P., van Doorn, L.-J., Bravo, J.C., Ruiz, B., Bravo, L.E., and Realpe, J.L. 2000. Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients. Am. J. Gastroenterol. 95, 564–566.PubMedGoogle Scholar
  11. De Francesco, V., Giorgio, F., Hassan, C., Manes, G., Vannella, L., Panella, C., Ierardi, E., and Zullo, A. 2010a. Worldwide H. pylori antibiotic resistance: A systematic review J. Gastrointestin. Liver Dis. 19, 409–414.Google Scholar
  12. De Francesco, V., Zullo, A., Perna, F., Giorgio, F., Hassan, C., Vannella, L., Panella, C., Vaira, D., and Ierardi, E. 2010b. Helicobacter pylori antibiotic resistance and [13C]urea breath test values. J. Med. Microbiol. 59, 588–591.PubMedCrossRefGoogle Scholar
  13. De Francesco, V., Zullo, A., Ierardi, E., Giorgio, F., Perna, F., Hassan, C., Morini, S., Panella, C., and Vaira, D. 2010c. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J. Antimicrob. Chemother. 65, 327–332.PubMedCrossRefGoogle Scholar
  14. Duque-Jamaica, R., Arévalo-Galvis, A., Poutou-Piñales, R.A., and Trespalacios-Rangel, A.A. 2010. Sequential statistical improvement of the liquid cultivation of Helicobacter pylori. Helicobacter 15, 303–312.PubMedCrossRefGoogle Scholar
  15. Fontana, C., Favaro, M., Minelli, S., Criscuolo, A.A., Pietroiusti, A., Galante, A., and Favalli, C. 2002. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob. Agent Chemother. 46, 3765–3769.CrossRefGoogle Scholar
  16. Graham, D.Y., Lu, H., and Yamaoka, Y. 2008. Therapy for Helicobacter pylori infection can be improved. Drugs 68, 725–736.PubMedCrossRefGoogle Scholar
  17. Graham, D.Y., Malaty, H.M., Evans, D.G., Evans, D.J., Klein, P.D., and Adam, E. 1991. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterol. 100, 1495–1501.Google Scholar
  18. Henao, S.C., Quiroga, A., Martínez, J.D., and Otero, W. 2009. Resistencia primaria a la claritromicina en aislamientos de Helicobacter pylori. Rev. Col. Gastroenterol. 24, 110–114.Google Scholar
  19. Hirata, K., Suzuki, H., Nishizawa, T., Tsugawa, H., Muraoka, H., Saito, Y., Matsuzaki, J., and Hibi, T. 2010. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J. Gastroenterol. Hepatol. 25, Suppl 1, S75–S79.PubMedCrossRefGoogle Scholar
  20. Kato, S., Fujimura, S., Udagawa, H., Shimizu, T., Maisawa, S., Ozawa, K., and Iinuma, K. 2002. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J. Clin. Microbiol. 40, 649–653.PubMedCrossRefGoogle Scholar
  21. Kato, M., Yamaoka, Y., Kim, J.J., Reddy, R., Asaka, M., Kashima, K., Osato, M.S., El-Zaatari, F.A.K., Graham, D.Y., and Kwon, D.H. 2000. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob. Agent Chemother. 44, 2214–2216.CrossRefGoogle Scholar
  22. Kim, K.S., Kang, J.O., Eun, C.S., Han, D.S., and Choi, T.Y. 2002. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J. Korean Med. Sci. 17, 599–603.PubMedGoogle Scholar
  23. Liu, Z., Zheng, P., and Yang, P. 2008. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J. Gastroenterol. 14, 5217–5222.PubMedCrossRefGoogle Scholar
  24. Maeda, S., Yoshida, H., Matsunaga, H., Ogura, K., Kawamata, O., Shiratori, Y., and Omata, M. 2000. Detection of clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 38, 210–214.PubMedGoogle Scholar
  25. Malfertheiner, P., Megraud, F., O’Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., and Kuipers, E.J. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772–781.PubMedCrossRefGoogle Scholar
  26. Marais, A., Monteiro, L., Occhialini, A., Pina, M., Lamouliatte, H., and Mégraud, F. 1999. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 44, 463–467.PubMedCrossRefGoogle Scholar
  27. Pan, Z.J., Su, W.W., Tytgat, G.N.J., Dankert, H., and Ende, A. 2002. Assessment of clarithromycin-resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China, by primer-mismatch PCR. J. Clin. Microbiol. 40, 259–261.PubMedCrossRefGoogle Scholar
  28. Rimbara, E., Fischbach, L.A., and Graham, D.Y. 2011. Optimal therapy for Helicobacter pylori infections. Nat. Rev. 8, 79–88.Google Scholar
  29. Rimbara, E., Noguchi, N., Kawai, T., and Sasatsu, M. 2008. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob. Agent Chemother. 52, 3465–3466.CrossRefGoogle Scholar
  30. Stone, G.G., Shortridge, D., Versalovic, J., Beyer, J., Flamn, R.K., Graham, D.Y., Ghoneim, A.T., and Tanaka, S.K. 1997. PCR oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agent Chemother. 41, 712–714.Google Scholar
  31. Taylor, D.E., Ge, Z., Purych, D., Lo, T., and Hiratsuka, K. 1997. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agent Chemother. 41, 2621–2628.Google Scholar
  32. Trespalacios, A.A., Otero Regino, W., and Mercado Reyes, M. 2010. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Rev. Col. Gastroenterol. 25, 31–38.Google Scholar
  33. Vakil, N. and Megraud, F. 2007. Eradication therapy for Helicobacter pylori. Gastroenterol. 133, 985–1001.CrossRefGoogle Scholar
  34. Vallejos, M.C., Garrido, O.L., Cáceres, L.D., Madrid, A.M., Defilippi, C., Defilippi, C.C., and Toledo, A.H. 2007. Prevalencia de la resistencia a metronidazol, claritromicina y tetraciclina en Helicobacter pylori aislado de pacientes de la Región Metropolitana. Rev. Méd. Chile 135, 287–293.PubMedCrossRefGoogle Scholar
  35. van Doorn, L.J., Glupczynski, Y., Kusters, J.G., Megraud, F., Midolo, P., Maggi-Solca, N., Queiroz, D.M.M., Nouhan, N., Stet, E., and Quint, W.G.V. 2001. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob. Agent Chemother. 45, 1500–1504.CrossRefGoogle Scholar
  36. Versalovic, J., Osato, M.S., Spakovsky, K., Dore, M.P., Reddy, R., Stone, G.G., Shortridge, D., Flamm, R.K., Tanaka, S.K., and Graham, D.Y. 1997. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40, 283–286.PubMedCrossRefGoogle Scholar
  37. Yamaoka, Y., Kodama, T., Kita, M., Imanishi, J., Kashima, K., and Graham, D.Y. 1999. Relation between clinical presentation, Helicobacter pylori density, interleukin 1 and 8 production, and cagA status. Gut 45, 804–811.PubMedCrossRefGoogle Scholar

Copyright information

© The Microbiological Society of Korea and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Alba A. Trespalacios
    • 1
    Email author
  • William Otero
    • 2
    • 3
  • Jorge E. Caminos
    • 4
  • Marcela M. Mercado
    • 1
  • Jenny Ávila
    • 1
  • Liliana E. Rosero
    • 1
  • Azucena Arévalo
    • 1
  • Raúl A. Poutou-Piñales
    • 5
  • David Y. Graham
    • 6
    • 7
  1. 1.Infectious Diseases Group, Microbiology Department, Science FacultyPontificia Universidad JaverianaBogotá, D.C.Colombia
  2. 2.Gastroenterology Unit. Clínica FundadoresBogotá, D.C.Colombia
  3. 3.Universidad Nacional de ColombiaBogotá, D.C.Colombia
  4. 4.Biochemistry UnitUniversidad Nacional de ColombiaBogotá, D.C.Colombia
  5. 5.Molecular Biotechnology Laboratory, Environment and Industrial Biotechnology Group (GBAI), Microbiology Department, Science FacultyPontificia Universidad JaverianaBogotá, D.C.Colombia
  6. 6.Department of MedicineMichael E. DeBakey Veterans Affairs Medical CenterHoustonUSA
  7. 7.Baylor College of MedicineHoustonUSA

Personalised recommendations